Trinity Biotech (TRIB)
(Delayed Data from NSDQ)
$2.17 USD
-0.33 (-13.20%)
Updated Aug 28, 2024 03:55 PM ET
After-Market: $2.11 -0.06 (-2.76%) 7:36 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Brokerage Reports
Trinity Biotech PLC [TRIB]
Reports for Purchase
Showing records 1 - 20 ( 105 total )
Company: Trinity Biotech PLC
Industry: Medical - Products
Company: Trinity Biotech PLC
Industry: Medical - Products
Company: Trinity Biotech PLC
Industry: Medical - Products
2Q:24 Preannounced Revenue Above Our Estimate; Forecast Double-Digit Revenue Rebound In
Provider: Sidoti CSR
Analyst: Research Department
Company: Trinity Biotech PLC
Industry: Medical - Products
Company: Trinity Biotech PLC
Industry: Medical - Products
2Q:23 Sales Topped Our Estimate; Still Forecast Sales, Earnings Rebound With Increased Focus On Faster-Growing Diabetes Products
Provider: Sidoti CSR
Analyst: Research Department
Company: Trinity Biotech PLC
Industry: Medical - Products
Company: Trinity Biotech PLC
Industry: Medical - Products
1Q:23 Revenue Below Expectations; Forecast 2024 Sales, Earnings Rebound With Increased Focus On Faster-Growing Diabetes Products
Provider: Sidoti CSR
Analyst: Research Department
Company: Trinity Biotech PLC
Industry: Medical - Products
Expect A Loss 1Q:23 Loss, On Lower Covid Revenue, Higher Interest Expenses,Maintain $4 Target
Provider: Sidoti CSR
Analyst: Research Department
Company: Trinity Biotech PLC
Industry: Medical - Products
Divesting Fitzgerald Life Sciences Business Should Focus Trinity On Faster-Growing Diabetes Monitoring Products, Strengthen Balance Sheet; Maintain $4 Price Target
Provider: Sidoti CSR
Analyst: Research Department
Company: Trinity Biotech PLC
Industry: Medical - Products
4Q:22 Revenue In line With Expectations; HIV Screening Test Adopted In Kenya
Provider: Sidoti CSR
Analyst: Research Department
Company: Trinity Biotech PLC
Industry: Medical - Products
3Q:22 Results In line With Expectations, Excluding Non-Cash Charges,Maintain $4 Price Target
Provider: Sidoti CSR
Analyst: Research Department
Company: Trinity Biotech PLC
Industry: Medical - Products
Expect A Loss In 3Q:22, On Lower Covid Revenue, Higher Interest Expenses
Provider: Sidoti CSR
Analyst: Research Department
Company: Trinity Biotech PLC
Industry: Medical - Products
Reinitiate Coverage of Trinity Biotech Plc With A $4 Price Target
Provider: Sidoti CSR
Analyst: Research Department
Company: Trinity Biotech PLC
Industry: Medical - Products
ValuEngine Detailed Valuation Report for TRIB
Provider: ValuEngine, Inc
Company: Trinity Biotech PLC
Industry: Medical - Products
We are dropping coverage of TRIB shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Trinity Biotech PLC
Industry: Medical - Products
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Trinity Biotech PLC
Industry: Medical - Products
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Trinity Biotech PLC
Industry: Medical - Products
Company: Trinity Biotech PLC
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trinity Biotech PLC
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.